PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough ...

Blood-based Shield Multi-Cancer Detection (MCD) test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy Results informed National Cancer Institute ...

Guardant HealthGH is Monday's IBD Stock Of The Day. Shares broke out of a cup base as enthusiasm builds for the company's multi-cancer detection blood test. This month, Guardant launched Shield as a ...

Guardant Health can prove to the market they have a competitive product in Shield that can gain a foothold in the roughly 50m unscreened CRC patient population. Shield's strongest adherence rate, with ...